The global induced pluripotent stem cells market size was valued at USD 1.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.61% from 2023 to 2030. The market for induced pluripotent stem cells (iPSCs) is driven by the increased use of stem cell therapies, a growing biotechnology industry with better investment opportunities, and an increase in the prevalence of chronic diseases. The wide range of clinical applications of induced pluripotent stem cells and new technological developments of iPSCs are additional drivers that are projected to fuel the expansion of the global market.
The COVID-19 pandemic has posed huge hurdles to the healthcare sector. During the COVID-19 pandemic, all outpatient procedures were delayed or restricted to minimize the risk of transmission of the virus, as most chronic therapies were deemed non-urgent. Several scientific projects were halted during the COVID-19 timeframe. During the outbreak, however, research on the SARS-CoV-2 infection accelerated dramatically. A study titled "iPS cell-based disease modeling & prospective immune-based therapy for COVID-19," published in the journal Cytotherapy in March 2022, investigated the modeling of SARS-CoV-2 infection in humans to aid drug screening and discovery.
iPSC’s develop from cells from the blood or skin that have been transformed into an embryonic-like pluripotent state, allowing the generation of an endless source of all sorts of human cells required for therapeutic applications. The distinct features of induced pluripotent stem cells open up a wide range of biopharmaceutical applications. iPSCs are also employed for toxicological testing, disease modeling, high throughput, including target selection. This stem cell type has the potential to revolutionize drug development by providing physiologically feasible cells for tool discovery, chemical identification, & target validation. It is a revolutionary medical therapy used to treat cardiac arrhythmias as well as cancers of the liver, prostate, kidney, lung, as well as other organs. For instance, in January 2023, FUJIFILM Cellular Dynamics, Inc. announced the company has reached an agreement to give Novo Nordisk A/S, a non-exclusive license to use its iPSC platform for the development as well as distribution of iPSC-derived cell therapies with an emphasis on treating severe chronic diseases.
Rising government expenditure and increased awareness of stem cell research throughout organizations are also expected to boost demand for induced pluripotent stem cells. For instance, November 2020, FUJIFILM Cellular Dynamics, Inc. and Lonza Walkersville, Inc. announced a global agreement. Through agreements for licensing, the agreement enables pharmaceutical companies to take benefit from each other's expertise and equipment for the development of iPSCs. The increasing prevalence of chronic diseases, as well as the usage of stem cells in their therapy, will boost induced pluripotent stem cells industry development potential.
Furthermore, the increased use of tailored medications for various illness therapies is fueling the expansion of the iPSC market. A paper titled "Precision regenerative medicine," which was first published in the journal Stem Cell Research & Therapy in January 2021, examined the rise of precision or personalized medicine in the medical and surgical fields. According to the report, induced pluripotent stem cells are essential in the personalized medicines segment since they have various advantages over other stem cells.
The increased number of induced pluripotent stem cell-based research investigations is significantly growing market growth. There are currently over 120 clinical trials using iPSCs for disease interventions or the development of iPSC products. Furthermore, the benefits of induced pluripotent stem cells, such as the removal of animal models and the flexibility of ethical considerations connected with embryonic stem cells, drive market expansion. This has resulted in a favorable market for induced pluripotent stem cells -based medicines from a variety of commercial companies.
However, the high expenses involved with stem cell research, as well as the longer time required to develop & deploy iPSC, are projected to stymie the global iPSC industry. Furthermore, ethical issues about stem cell research as well as therapies are projected to limit worldwide induced pluripotent stem cell demand to a certain extent.
The fibroblasts segment held the largest market share of 30.48% in 2022. Fibroblasts are the skin's most accessible cells and have received a lot of interest in cell therapy. Using dermal fibroblasts' regeneration capacity opens up new avenues for developing cell-based therapeutics to treat skin problems. These cells are primarily responsible for the synthesis of glycosaminoglycans, collagens, including extracellular matrix components that support the structural integrity of the skin. Several preclinical investigations have revealed that allogeneic as well as autologous dermal fibroblasts can be used to treat burn ulcers, wound healing, and hereditary skin problems. Induced pluripotent stem cells (iPSCs) derived from fibroblasts & gene-edited fibroblasts are thus potential treatments for treating skin problems. Hence, propelling the market growth.
The hepatocytes segment is expected to witness the fastest CAGR of 13.21% from 2023 to 2030. The growing liver disease, rising sedentary lifestyle, and others are contributing the market growth. Such advancements are major factors expected to boost market growth. As per the National Institutes of Health, in March 2023, one out of every 25 deaths globally is caused by liver disease, which causes two million deaths annually and accounts for 4% of all deaths; almost two-thirds of all hepatic-related deaths are male.
The drug development segment held the largest market share of 49.09% in 2022. As chronic diseases become more prevalent around the world, The Partnership to Fight Chronic Disease (PFCD) projected that more than 130 million Americans are plagued by chronic diseases such as diabetes, asthma, heart issues, and cancer. According to the PFCD, more than one in every two Americans has at least one chronic disease, and one in every three has two or more chronic diseases. As a result, the prevalence of chronic diseases drives the desire for disease understanding. The iPS cells are frequently used in disease modeling, resulting in the development and discovery of novel treatment methods. Market participants like Evotec SE, for example, have established iPSC infrastructure that provides a platform for high efficiency, reproducible, & robust drug screening.
The tissue engineering & regenerative medicine segment is expected to witness the fastest CAGR of 12.21% from 2023 to 2030The market for induced pluripotent stem cells is in its early stages, owing to their ability to generate any cell or tissue the body may require treating a wide range of diseases such as diabetes, spinal cord injury, leukemia, or heart disease. These cells can potentially be personalized to provide a perfect genetic match for each patient. Furthermore, these cells are extremely important in understanding the very early stages of human development and provide the ability to construct personalized, rejection-proof tissues and cells for transplantation. This is expected to increase the revenue share of tissue engineering & regenerative medicine in the market.
The pharmaceutical & biotechnology companies segment held the largest market share of 59.77% in 2022. Revenue generation in this area is driven by the availability and use of numerous derived cells with iPSCs products. Biotechnology and pharmaceutical businesses are accelerating new product development in order to capitalize on the commercial opportunity of stem cell-based therapies. For example, Fate Therapeutics announced in October 2022 that it will present preclinical and clinical results from numerous iPSC product platforms at the Society for Immunotherapy of Cancer (SITC) meeting in November 2022. This highlights the market's substantial iPSCs product pipeline, which is supporting growth.
The academic & research institutes segment is expected to witness the fastest CAGR of 11.18% from 2023 to 2030. iPSCs are used in numerous academic and clinical studies because of their many potential uses. The increasing use of iPSCs in regenerative investigations bodes well for bringing this technology into therapeutic usage. For example, in March 2022, Indiana University researchers collaborated with different organizations to examine the utilization of human iPSC for the restoration of visual abilities in diabetic patients. Furthermore, the expanding research environment for assessing the safety & efficacy of iPSC-based treatments will fuel market expansion.
North America held the largest market share of 42.36% of the global market in 2022. Some of the primary drivers driving market expansion in North America are the increasing employment of highly advanced systems and technologies in the development of drugs, toxicity testing, or disease modeling, as well as the region's expanding adoption of stem cell therapies.
In December 2020, REPROCELL launched a customized iPSC creation service, as well as a new B2C website to market the "Personal iPS" service. This service prepares and saves an individual's iPSCs for damage or disease regeneration therapy in the future. Thus, the growing need for induced pluripotent stem cells, together with increased investment in the health care sector, is expected to drive market expansion in this area.
Asia Pacific is expected to experience the fastest CAGR of 11.56% from 2023 to 2030 Key factors such as extensive low-cost stem cell-based research, developing economies, improvements in healthcare systems, and rising awareness of the possibility of tailored treatments will boost revenue growth during the anticipated period. Furthermore, the existence of several start-ups, academic universities, multinational company collaborations, and new product/service launches in this region will add to Asia Pacific’s growth.
The continuous demand for iPSC for multiple applications has created numerous market opportunities for major players to capitalize on. For instance, in March 2023, Tempo Bioscience announced the launch of novel human induced pluripotent stem cell (iPSC) derived cell products & cell-based services. Some prominent players in the global induced pluripotent stem cells market include:
STEMCELL Technologies Inc.
Cellular Engineering Technologies Inc.
Takara Bio, Inc.
Axol Bioscience Ltd.
Fate Therapeutics, Inc.
FUJIFILM Cellular Dynamics, Inc.
Cynata Therapeutics Limited
Astellas Pharma Inc.
Market size value in 2023
USD 1.52 billion
Revenue forecast in 2030
USD 3.09 billion
CAGR of 10.61% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Derived cell type, application, end-user, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., REPROCELL Inc., Takara Bio, Inc.
Axol Bioscience Ltd., Fate Therapeutics, Inc., FUJIFILM Cellular Dynamics, Inc., Cynata Therapeutics Limited , Evotec SE, Astellas Pharma Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, grand view research has segmented the global induced pluripotent stem cells market report based on derived cell type, application, end-user, and region:
Derived Cell Type Outlook (Revenue, USD Million, 2018 - 2030)
Application Outlook (Revenue, USD Million, 2018 - 2030)
Tissue Engineering & Regenerative Medicine
Cardiovascular and Myocardial Infraction
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global induced pluripotent stem cells market size was estimated at USD 1.40 billion in 2022 and is expected to reach USD 1.52 billion in 2023.
b. The global induced pluripotent stem cells market is expected to grow at a compound annual growth rate of 10.61% from 2023 to 2030 to reach USD 3.09 billion by 2030.
b. The fibroblasts segment held the largest market share of 30.48% in 2022. Fibroblasts are the skin's most accessible cells and have received a lot of interest in cell therapy.
b. Some prominent players in the global induced pluripotent stem cells market include STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., REPROCELL Inc., Takara Bio, Inc., Axol Bioscience Ltd., Fate Therapeutics, Inc., FUJIFILM Cellular Dynamics, Inc., Cynata Therapeutics Limited, Evotec SE, Astellas Pharma Inc.
b. The market for induced pluripotent stem cells (iPSCs) is driven by the increased use of stem cell therapies, a growing biotechnology industry with better investment opportunities, and an increase in the prevalence of chronic diseases. The wide range of clinical applications of induced pluripotent stem cells and new technological developments of iPSCs are additional drivers that are projected to fuel the expansion of the global induced pluripotent stem cells market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."